Cargando…
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
Antibody drug conjugates (ADCs) are an emerging new class of targeted therapeutics for cancer that use antibodies to deliver cytotoxic drugs to cancer cells. There are two FDA approved ADCs on the market and over 30 ADCs in the clinical pipeline against a number of different cancer types. The struct...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596897/ https://www.ncbi.nlm.nih.gov/pubmed/25446773 http://dx.doi.org/10.1007/s11095-014-1584-z |